Member Info for Dosanddonts

Makes no difference what people say here, as I’ve always said sales is the merit of the product, problem is sales will rise & fall as the market adapts , we are non the wiser after 24 update! My only issue is they give no update on the UK which had high sales & eventually captured 20% of the ED market after 1 year? Where is it now??? US sales are key & the Haleon Q1 update will move it either way!!!! I’m hoping upwards but stuck here currently as I do see a return eventually just wish I’d sold & bought back in! But I’m useless at that!!!

What happened to the time when you setup a business and took minimum salary until the business could afford a decent salary that had been earned? Too easy to setup an Aim company & too many institutional investors backing them with no curtailment of salaries! LB involved now but too late they’ve already emptied the till thieving Twats!

In 2020 total staff 13 costing £2m, 3 directors took home £1m! Over doubled their salaries in 5 years

If Lombard increased their % to 51% costing around £6m, they could save £2m annually by removing JB & AH for gross incompetence & recover that £6m in 3 years? I feel without those two idiots the SP would increase just from removing them so may see a return even quicker!

How do you control costs when the wage bill is £5.2m, 17 staff! 3 directors took home £800k each averaged then 14 staff each took home £200k each averaged!

JB took home £1m salary in 2023 & 2024, for a loss making company that’s disgraceful

Last one but they also said they signed a 3 year CMO deal so does that mean they will be hit with more penalties for 2025 & 2026, & larger due to reduced volumes as forecasted??

So the min order penalty is on FUM not commercial partners, meaning 60% production costs and a £730k penalty 10%, so 70% production costs?? From 2023 costs of 40%, that dosnt sit well IMO moving UK CMO with lower cost base to EU CMO. Everything is hanging on Haleon to pull a rabbit out the hat!

Https://presentations.investormeetcompany.com/investor-meet-company/futura-medical-plc-full-year-results?bmid=1d1e2a48c930

Noticed in the video chat this morning we got it’s a shame about the share price dropping but the slow uptake was to be expected with a new OTC product like Eroxon with the stigma involved?? Well why did the forecasted predictions you were part of not reflect that!! Absolute IDIOTS! That was the reason for the drop the over ambitious forecasts which again you wasted our money on. Anyone notice the increased manufacturing costs 60% versus 40% 2023? How much of that was CMO setup costs or are we saying that with current volumes we lose 60% of sales before admin costs then taxes?

I’m hoping they shine some light on actual retail sales as this would give the market some confidence & an indication as to how it is selling, $50mil US retail sales still means good sales just not what was hoped for early doors! Don’t think the spoke & mirrors is going to cut it this time & hoping Lombard have been teaching them how to report!!!!

Maybe the drop is because Amazon US sales have dropped to 9k, so held at 20k+ for months then within a few weeks dropped from 20k+ to 9k? Is this because sales have shifted to retail or what?? Also why are they selling a value 8 pack for over double what a 4 pack costs on Amazon US??

13:30pm RNs end of year results 15th April, as for people buying another pint, we aren’t we are just not going to the throw the one we have away as paid good money. Better than sitting in a pub with no pint & looking at every else’s now that’s sad!

that is the million dollar question here why are they delayed?? my god jb gives market updates that where unnecessary which decimated the sp, he has informed the market of year end results in april so where are they?? are they expecting positive q1 results which generally they don’t report on as only report twice a year, to be included?? if so why update the market of the 50% sales/revenue reduction? i think personally they are having their ****s whipped by lombard or something bigger is going on here! problem with these idiots, is that going to be positive or negative? but let’s face it can things get much worse.

I personally never leave reviews unless it was really bad so a product that didn’t work for you in this case, would be a very good reason to leave a really negative review! But Lord comments on this share even though he is not invested, so guessing he is the kind of person who would leave a review as got nothing better to do! Hopefully most people are like me & it would appear so, not like the very small percentage of Lord’s!!

This product has never denied it works for only 60% of people it’s on the Tin, & to be honest the reviews reflects that it either works or it doesn't. Would not stop people trying it IMO! PDE5 inhibitors cause all sorts of side effects, they can kill you in extreme circumstances yet still people try them as was the only option!

In most new ED patients you would try treatments starting with the least invasive with regard to side effects, so this will capture new ED customers looking for treatment with minimal side effects! Issue here is most people are already on PDE5 inhibitors so trying to convince people to change when it works for them is difficult & will take time.

this is stupidity the product works just targeting the market is taking a little longer then expected! the bod are useless i agree but product still works just time will tell! but we cud do with getting rid of jb & ah as a matter of urgency! wouldn’t let them clean my toilet! or my **** hole!!!!!!!!!

These idiots are ploughing ahead with new R&D products when they are expecting a loss in 2025 & only have capital to H2 2026??? Lombard there to stop the dilution of their shares. Now 9 days late in announcing FY24 results?? Something going on as the fu ck wits are always like clockwork! Shi t happening & hopefully positive!

If Haleon came with an offer why would they sell that tells the story they are on to a winner & way under valued at 40p T/O valuation someone made!!!!!

It’s has been pumped & dumped over the years as an R&D setup, it now has a product with sales, this is what will drive the SP, all R&D is now linked to the one product Eroxon. So it has to sell or that’s it IMO regardless of other linked products

The answer to 4-5x is revenue & sales! Simple! Potentially more!